SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFC14A - Definitive proxy statement, contested solicitations:
SEC Accession No. 0001564590-22-013569
Filing Date
2022-04-05
Accepted
2022-04-05 16:08:02
Documents
6

Document Format Files

Seq Description Document Type Size
1 DEFC14A atha-defc14a_20220519.htm DEFC14A 1329332
2 GRAPHIC ggbwnhpj5pdf000003.jpg GRAPHIC 7079
3 GRAPHIC ggbwnhpj5pdf000004.jpg GRAPHIC 80875
4 GRAPHIC ggbwnhpj5pdf000001.jpg GRAPHIC 13134
5 GRAPHIC ggbwnhpj5pdf000002.jpg GRAPHIC 6431
6 GRAPHIC ggbwnhpj5pdf000005.jpg GRAPHIC 81428
  Complete submission text file 0001564590-22-013569.txt   1592040
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filed by) CIK: 0001620463 (see all company filings)

IRS No.: 453368487 | Fiscal Year End: 1231
Type: DEFC14A
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Subject) CIK: 0001620463 (see all company filings)

IRS No.: 453368487 | Fiscal Year End: 1231
Type: DEFC14A | Act: 34 | File No.: 001-39503 | Film No.: 22806833
SIC: 2836 Biological Products, (No Diagnostic Substances)